Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

De Novo Kidney Transplantation

Conditions

De Novo Kidney Transplantation

Trial Timeline

Dec 1, 2007 → Sep 1, 2009

NCT ID

NCT00617604

About Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids

Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids is a phase 2 stage product being developed by Astellas Pharma for De Novo Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00617604. Target conditions include De Novo Kidney Transplantation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00617604	Phase 2	Completed	Dec 1, 2007	Sep 1, 2009	De Novo Kidney Transplantation

Competing Products

19 competing products in De Novo Kidney Transplantation

See all competitors

Product	Company	Stage	Hype Score
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	85
Prograf + Advagraf	Astellas Pharma	Approved	85
ATG-F	Astellas Pharma	Approved	85
Advagraf + Prograf + Corticosteroid + Mycophenolate mofetil	Astellas Pharma	Approved	85
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	85
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase	AbbVie	Phase 1	33
Birabresib Dose 20 mg	Merck	Phase 1	33
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	85
Enteric-Coated Mycophenolate Sodium (EC-MPS)	Novartis	Approved	85
everolimus + cyclosporine + Prednison (continuous steroids)	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	77
AEB071	Novartis	Phase 1	33
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	77
EC-MPS	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS), valsartan	Novartis	Phase 3	77
everolimus	Novartis	Phase 3	77
Prograf + Tacrolimus Hexal	Novartis	Approved	85
Mycophenolate Mofetil	Roche	Approved	85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved